Ukr.Biochem.J. 2022; Volume 94, Issue 2, Mar-Apr, pp. 31-37

doi: https://doi.org/10.15407/ubj94.02.031

Comparison of adjuvant properties of chitosan during oral and subcutaneous immunization of mice with BSA

M. R. Kozak1*, I. M. Petruh1, V. V. Vlizlo2

1Institute of Animal Biology NAAS, Lviv, Ukraine;
2Stepan Gzhytskyi National University of Veterinary Medicine and Biotechnologies Lviv, Ukraine;
*e-mail: mariyarkozak@gmail.com

Received: 15 December 2021; Accepted: 01 July 2022

Vaccination is the best method to prevent the spread of infectious diseases, its disadvantages are side effects. Potentially safe DNA, RNA or protein molecules possess antigenic properties, but are low-immunogenic and therefore require conjugation with an adjuvant. The aim of the research was to evaluate Chitosan (CS) potency as an adjuvant and compare its effectiveness depending on the route of drug administration. The experiments were carried out on 3 groups of BALB/c mice. Mice of the first group were injected subcutaneously with 20 µl of a mixture of CS (3.3 mg/kg) and BSA (1.7 mg/kg). The mixture of CS and BSA at the same doses and volume was administered orally to mice of the second experimental group. The third group – control – unvaccinated mice. Anti-BSA antibody levels were measured by ELISA. Aspartate aminotransferase, alanine aminotransferase activity and cholesterol, creatinine and urea levels were determined in the serum. It was found that both subcutaneous and mucosal immunizations provided a 2-fold increase in anti-BSA antibody titers against the background of maintaining all biochemical blood parameters at the level of the physiological norm. However, AST activity in the serum of oral-immunized mice was elevated as compared to subcutaneous-immunized mice. Serum cholesterol level in the group of subcutaneously immunized mice and creatinine and urea levels in both experimental groups were reduced compared to the control. It is concluded that oral immunization with CS is the optimal route for antigen-specific IgG antibody response induction.

Keywords: , , , ,


References:

  1. Swedish Council on Health Technology Assessment. Vaccines to Children: Protective Effect and Adverse Events: A Systematic ReviewSummary and conclusions. SBU Systematic Review Summaries. SBU Yellow Report No. 191. 2009.
  2. Stratton K, Ford A, Rusch E, Wright-Clayton E. Adverse Effects of Vaccines: Evidence and Causality. Committee to Review Adverse Effects of Vaccines, Institute of Medicine, National Academies Press (US). 2011. PubMed, CrossRef
  3. Fukuda S, Ishikawa K, Inuyama Y. Acute measles infection in the hamster cochlea. Acta Otolaryngol Suppl. 1994;514:111-116. PubMed, CrossRef
  4. Pruna D, Balestri P, Zamponi N, Grosso S, Gobbi G, Romeo A, Franzoni E, Osti M, Capovilla G, Longhi R, Verrotti A. Epilepsy and vaccinations: Italian guidelines. Epilepsia. 2013;54(Suppl 7):13-22. PubMed, CrossRef
  5. Muratori C, Bona R, Federico M. Lentivirus-based virus-like particles as a new protein delivery tool. Methods Mol Biol. 2010;614:111-124. PubMed, CrossRef
  6. Zurbriggen R. Immunostimulating reconstituted influenza virosomes. Vaccine. 2003;21(9-10):921-924. PubMed, CrossRef
  7. Apostólico Jde S, Lunardelli VAS, Coirada FC, Boscardin SB, Rosa DS. Adjuvants: Classification, Modus Operandi, and Licensing. J Immunol Res. 2016;2016:1459394. PubMed, PubMedCentral, CrossRef
  8. Kozak M, Mitina N, Zaichenko A, Vlizlo V. Anionic polyelectrolytehydrogel as an adjuvant for vaccine development. Sci Pharm. 2020;88(4):56. CrossRef
  9. Powell BS, Andrianov AK, Fusco PC. Polyionic vaccine adjuvants: another look at aluminum salts and polyelectrolytes. Clin Exp Vaccine Res. 2015;4(1):23-45. PubMed, PubMedCentral, CrossRef
  10. Kabanov VA. From synthetic polyelectrolytes to polymer-subunit vaccines. Pure Appl Chem. 2004;76(9):1659-1677. CrossRef
  11. Andrianov AK, Marin A, Roberts BE. Polyphosphazene polyelectrolytes: a link between the formation of noncovalent complexes with antigenic proteins and immunostimulating activity. Biomacromolecules. 2005;6(3):1375-1379. PubMed, CrossRef
  12. Payne LG, Jenkins SA, Woods AL, Grund EM, Geribo WE, Loebelenz JR, Andrianov AK, Roberts BE. Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine. Vaccine. 1998;16(1):92-98. PubMed, CrossRef
  13. Mutwiri G, Benjamin P, Soita H, Townsend H, Yost R, Roberts B, Andrianov AK, Babiuk LA. Poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influenza virus antigens. Vaccine. 2007;25(7):1204-1213. PubMed, CrossRef
  14. Dar A, Tipu M, Townsend H, Potter A, Gerdts V, Tikoo S. Administration of Poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) and Avian Beta Defensin as Adjuvants in Inactivated Inclusion Body Hepatitis Virus and its Hexon Protein-Based Experimental Vaccine Formulations in Chickens. Avian Dis. 2015;59(4):518-524. PubMed, CrossRef
  15. Awate S, Eng NF, Gerdts V, Babiuk LA, Mutwiri G. Caspase-1 Dependent IL-1β Secretion and Antigen-Specific T-Cell Activation by the Novel Adjuvant, PCEP. Vaccines (Basel). 2014;2(3):500-514. PubMed, PubMedCentral, CrossRef
  16. Sellborn A, Andersson M, Hedlund J, Andersson J, Berglin M, Elwing H. Immune complement activation on polystyrene and silicon dioxide surfaces. Impact of reversible IgG adsorption. Mol Immunol. 2005;42(5):569-574. PubMed, CrossRef
  17. Granum B, Gaarder PI, Groeng E, Leikvold R, Namork E, Lovik M. Fine particles of widely different composition have an adjuvant effect on the production of allergen-specific antibodies. Toxicol Lett. 2001;118(3):171-181. PubMed, CrossRef
  18. McNeela EA, Jabbal-Gill I, Illum L, Pizza M, Rappuoli R, Podda A, Lewis DJ, Mills KH. Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine. 2004;22(8):909-914. PubMed, CrossRef
  19.  Lampe AT, Farris EJ, Brown DM, Pannier AK. High- and low-molecular-weight chitosan act as adjuvants during single-dose influenza A virus protein vaccination through distinct mechanisms. Biotechnol Bioeng. 2021;118(3):1224-1243. PubMed, PubMedCentral, CrossRef
  20. Huang J, Mikszt JA, Ferriter MS, Jiang G, Harvey NG, Dyas B, Roy CJ, Ulrich RG, Sullivan VJ. Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge. Hum Vaccin. 2007;3(3):90-93. PubMed, CrossRef
  21. Ichinohe T, Ainai A, Tashiro M, Sata T, Hasegawa H. PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants. Vaccine. 2009;27(45):6276-6279. PubMed, CrossRef
  22. Wong-Chew RM, Islas-Romero R, García-García Mde L, Beeler JA, Audet S, Santos-Preciado JI, Gans H, Lew-Yasukawa L, Maldonado YA, Arvin AM, Valdespino-Gómez JL. Induction of cellular and humoral immunity after aerosol or subcutaneous administration of Edmonston-Zagreb measles vaccine as a primary dose to 12-month-old children. J Infect Dis. 2004;189(2):254-257. PubMed, CrossRef
  23. Bennett JV, Fernandez de Castro J, Valdespino-Gomez JL, Garcia-Garcia Mde L, Islas-Romero R, Echaniz-Aviles G, Jimenez-Corona A, Sepulveda-Amor J. Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: randomized trials in Mexican schoolchildren. Bull World Health Organ. 2002;80(10):806-812. PubMed, PubMedCentral
  24. De Serrano LO, Burkhart DJ. Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines. J Nanobiotechnol. 2017;15(1):83. PubMed, PubMedCentral, CrossRef
  25. Wang ZF, Wang MY, Yu DH, Zhao Y, Xu HM, Zhong S, Sun WY, He YF, Niu JQ, Gao PJ, Li HJ. Therapeutic effect of chitosan on CCl4‑induced hepatic fibrosis in rats. Mol Med Rep. 2018;18(3):3211-3218. PubMed, PubMedCentral, CrossRef
  26. Kozak MR, Oliynyk AV, Zaichenko OS, Vlizlo VV. Adjuvant properties of polymer based on acrylic acid. Ukr Biokhim Zhurn. 2013;85(3):69-73. (In Ukrainian). PubMed, CrossRef
  27. Nnamdi OA, Uchenna AR, Chinedum OU, Ugochukwu NC, Shedrack EO, Okechukwua EC. Safety evaluation in mice of the childhood immunization vaccines from two south-eastern states of Nigeria. Asian Pac J Trop Biomed. 2015;5(2):132-137. CrossRef
  28. Perkins FT, Sheffield F, Miller CL, Skegg JL. The comparison of toxicity of pertussis vaccines in children and mice. Symp Ser Immunobiol Standard. 1970;13:141-149.
  29. Mazzaccara C, Labruna G, Cito G, Scarfò M, De Felice M, Pastore L, Sacchetti L. Age-Related Reference Intervals of the Main Biochemical and Hematological Parameters in C57BL/6J, 129SV/EV and C3H/HeJ Mouse Strains. PLoS One. 2008;3(11):e3772. PubMed, PubMedCentral, CrossRef
  30. Okamoto Y, Inoue A, Miyatake K, Ogihara K, Shigemasa Y, Minami S. Effects of chitin/chitosan and their oligomers/monomers on migrations of macrophages. Macromol Biosci. 2003;3(10):587-590. CrossRef
  31. Zheng B, Wen ZS, Huang YJ, Xia MS, Xiang XW, Qu YL. Molecular Weight-Dependent Immunostimulative Activity of Low Molecular Weight Chitosan via Regulating NF-κB and AP-1 Signaling Pathways in RAW264.7 Macrophages. Mar Drugs. 2016;14(9):169. PubMed, PubMedCentral, CrossRef
  32. Rodrigues WF, Miguel CB, Napimoga MH, Oliveira CJF, Lazo-Chica JE. Establishing standards for studying renal function in mice through measurements of body size-adjusted creatinine and urea levels. Biomed Res Int. 2014;2014:872827. PubMed, PubMedCentral, CrossRef

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.